Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NMTC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Restatement (new) — Company must restate Q1 2026 financials due to revenue recognition errors totaling $529K.
- Material Weakness (new) — Internal control deficiency over customer purchase order evaluation led to premature revenue recognition.
NeuroOne to restate Q1 2026 results after $529K revenue overstatement from control failures
Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read
Key Changes
-
high
Company overstated Q1 2026 revenue by $529K and gross profit by $296K due to premature revenue recognition on modified customer purchase orders; losses were understated by the same amount
Item 4.02 verify on EDGAR → -
high
Audit Committee determined Q1 financials filed May 12 can no longer be relied upon and must be restated; amended 10-Q to be filed as soon as practicable
Item 4.02 verify on EDGAR → -
high
Root cause identified as inadequate internal controls over evaluating customer modified purchase orders; company states no intentional misconduct by management or employees
Item 4.02 verify on EDGAR → -
medium
Balance sheet as of March 31, 2026 overstated total assets by $296K and understated inventory by $233K
Item 4.02 verify on EDGAR → -
medium
Independent auditor Baker Tilly US, LLP has been notified of the restatement matters
Item 4.02 verify on EDGAR →
Summary
NeuroOne Medical Technologies disclosed that its Q1 2026 financial results, filed just 10 days earlier on May 12, contained material accounting errors requiring a full restatement. The company prematurely recognized $529,000 in revenue from customer orders that should not have been booked, overstating gross profit by $296,000 and making reported losses appear smaller than they actually were.
The errors stemmed from inadequate internal controls for evaluating modified customer purchase orders—a significant operational weakness for a small medical device company. For retail investors, this raises immediate concerns about the reliability of NeuroOne's financial reporting and the strength of its internal processes.
While management emphasized the errors were unintentional, the control deficiency suggests the company may lack the infrastructure to accurately track and report its business. The $529K overstatement is material for a company of NeuroOne's size, and the quick turnaround between filing and restatement is unusual. Watch for the amended 10-Q filing to assess the full scope of corrections and whether management identifies this as a material weakness in internal controls. Also monitor whether similar issues emerge in future quarters, which would signal deeper systemic problems.
Section-by-Section Diff
Event · Item 4.02 — Non-Reliance on Previously Issued Financial Statements
Item 4.02 — Non-Reliance on Previously Issued Financial Statements filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company’s previously issued interim financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed on May 12, 2026 (the “Previous Filing”), should no longer be relied upon and should be restated because of accounting errors relating to revenue recognition.
The Audit Committee determined that Q1 2026 financial statements filed on May 12, 2026 contain accounting errors and must be restated. The errors relate to revenue recognition issues stemming from inadequate internal controls over evaluating customer modified purchase orders. The company will file an amended 10-Q as soon as practicable.
Added in current filing · verify on EDGAR →
The Audit Committee and the Company’s management have discussed the matters disclosed in this Item 4.02 with the Company’s independent registered public accounting firm, Baker Tilly US, LLP.
The Audit Committee and management have informed the company's independent auditor, Baker Tilly US, LLP, about the restatement. This is standard procedure when previously issued financial statements can no longer be relied upon.
Event · Item 7.01 — Regulation FD Disclosure
Company announced intention to restate financial statements from a prior filing.
Added in current filing · verify on EDGAR →
On May 22, 2026, the Company issued a press release regarding its intention to restate the financial statements in the Previous Filing.
The company announced it intends to restate financial statements from a prior filing. Financial restatements typically indicate errors in previously reported results and can affect investor confidence. The specific nature, scope, and financial impact of the restatement are not detailed in this 8-K.
Event · Item 9.01 — Financial Statements and Exhibits
NEUROONE filed an 8-K attaching a press release dated May 22, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Exhibit | Number | Description | 99.1 | Press Release, dated May 22, 2026
The company attached a press release dated May 22, 2026 as Exhibit 99.1. The 8-K body does not disclose the content of the press release, so the nature and materiality of the announcement cannot be determined from this filing alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 25, 2026 · How we verify